道恩股份(002838.SZ):控股子公司擬收購中科先行13.22%股份
格隆匯 10 月 26日丨道恩股份(002838.SZ)公佈,公司")於2020年10月26日召開第四屆董事會第六次會議,審議通過了《關於控股子公司收購資產的議案》,同意公司控股子公司青島海爾新材料研發有限公司(以下簡稱"海爾新材料")使用自有資金收購海爾集團公司(以下簡稱"海爾集團")持有的中科先行工程塑料國家工程研究中心股份有限公司(以下簡稱"中科先行")13.22%股份,並授權經營管理層辦理相關事宜。轉讓對價為人民幣 1311.6133 萬元。
此次交易完成後,海爾新材料持有中科先行13.22%股份,公司間接持有中科先行的股份。 同日,海爾新材料與交易對方簽訂了《股份轉讓協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.